Experimental evidence and network pharmacology-based analysis reveal the molecular mechanism of Tongxinluo capsule administered in coronary heart diseases | Zendy

Guode Li | Zendy; Qingbo Xu | Zendy; Kedong Han | Zendy; Wenhe Yan | Zendy; Huang Chao-pei | Zendy

Open Access

Experimental evidence and network pharmacology-based analysis reveal the molecular mechanism of Tongxinluo capsule administered in coronary heart diseases

Author(s) -

Guode Li,

Qingbo Xu,

Kedong Han,

Wenhe Yan,

Huang Chao-pei

Publication year - 2020

Publication title -

bioscience reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.938

H-Index - 77

eISSN - 1573-4935

pISSN - 0144-8463

DOI - 10.1042/bsr20201349

Subject(s) - kegg , mechanism (biology) , biology , systems pharmacology , computational biology , bioinformatics , medicine , gene , pharmacology , gene ontology , genetics , gene expression , drug , philosophy , epistemology

Tongxinluo (TXL) capsule, a polypharmacy derived from traditional Chinese medicine (TCM), has been widely used in coronary heart disease (CHD), while the underlying mechanism of TXL capsule is still unclear. The present study aimed at investigating the underlying mechanism of TXL acting on CHD patients and providing substantial evidence in molecular evidence by means of a network pharmacological analysis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research